Since hepatic inflammation and fibrosis are inter-related events—both being consequences of the continuum of immunological activities in chronic liver diseases—the inflammatory burden must be considered as a possible limitation to the use of sCD163 and sMR as biomarkers of liver fibrosis. The gene discussed is CD163; the disease is Hepatic fibrosis.